Skip to main content
SpringerLink
Log in

Molekulare Pathologie bösartiger pulmonaler und pleuraler Tumoren

  • Chapter
Book cover Molekularmedizinische Grundlagen von nicht-hereditären Tumorerkrankungen

Part of the book series: Molekulare Medizin ((MOLMED))

  • 56 Accesses

Zusammenfassung

Die Therapie und die Prognase bösartiger Tumoren der hängen entscheidend von

  • der Tumorgröße,

  • dem Tumorstadium und

  • der histopatholosgischen Charakterisierung zum Zeitpunkt der Diagnosestellung ab.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Abeloff MD, Eggleston JC, Mendelsohn G, Ettinger DS, Baylin SB (1979) Changes in morphologie and biochemical characteristics of small cell carcinoma of the lung. Am J Med 66:757–764

    PubMed  CAS  Google Scholar 

  • Ahrendt SA, Chow JT, Yang SC et al. (2000) Alcohol consumption and cigarette smoking increase the frequency of p53 mutations in non-small cell lung cancer. Cancer Res 60:3155–3159

    PubMed  CAS  Google Scholar 

  • Albelda SM, Wiewrodt R, Zuckerman JB (2000) Gene therapy for lung disease: hype or hope? Ann Intern Med 132:649–660

    PubMed  CAS  Google Scholar 

  • Albrechtsen N, Dornreiter I, Grosse F, Kim E, Wiesmüller L, Deppert W (1999) Maintenance of genomic integrity by p53: complementary roles for activated and non-activated p53. Oncogene 18:7706–7717

    PubMed  CAS  Google Scholar 

  • Antonia SJ, Sotomayor E (2000) Gene therapy for lung cancer. Curr Opin Oncol 12:138–142

    PubMed  CAS  Google Scholar 

  • Baker SJ, Fearon ER, Nigro JM et al. (1989) Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 244:217–221

    PubMed  CAS  Google Scholar 

  • Bartsch H, Hollstein M, Mustonen R et al. (1995) Screening for putative radon-specific p53 mutation hotspot in German uranium miners. Lancet 346:121

    PubMed  CAS  Google Scholar 

  • Baselga J (1999) New horizons: gene therapy for cancer. Anticancer Drugs [Suppl 1] 10:S39–S42

    PubMed  CAS  Google Scholar 

  • Bates S, Vousden K (1999) Mechanisms of p53-mediated apoptosis. Cell Mol Life Sci 55:28–37

    PubMed  CAS  Google Scholar 

  • Benezra JM, Kornstein MJ, Grimes MM, Krystal G (1994) Small cell carcinomas of the lung express the Bcl-2 protein. Am J Pathol 145:1036–1040

    CAS  Google Scholar 

  • Bennett WP, Colby TV, Travis WD et al. (1993) p53 protein accumulates frequently in early bronchial neoplasia. Cancer Res 53:4817–4822

    PubMed  CAS  Google Scholar 

  • Betz E, Papadopoulos T, Buchwald J, Dämmrich JR, MüllerHermelink HK (1995) Surfactant protein gene expression in metastatic and micrometastatic pulmonary adenocarein omas and other non small cell lung carcinomas: detection by reverse transcriptase-polymerase chain reaction. Cancer Res 55:4283–4286

    PubMed  CAS  Google Scholar 

  • Biome O (1993) Geschichte, Ursachen und Verlaufs schilderung der “Schneeberger Lungenkrankheit” bzw. der Berufskrankheit Nr. 92 der ehemaligen Deutschen Demokratischen Republik/Nr. 2402 der Bundesrepublik Deutschland. BG 104:38–46

    Google Scholar 

  • Brennan J, O’Connor T, Makuch RW et al. (1991) Myc family amplification in 107 tumors and tumor cell lines from patients with small cell lung cancer treated with different combination chemotherapy regimes. Cancer Res 51: 1708–1712

    PubMed  CAS  Google Scholar 

  • Bülzebruck H, Drings P (1991) Classification of lung cancer: first experiences with the new TNM-dassification (4th edn). Eur Respir J 4:1197–2206

    PubMed  Google Scholar 

  • Bülzebruck H, Bopp R, Drings P et al. (1992) New aspects in the staging of lung cancer: prospective validation of the International Union Against Cancer TNM dassification. Cancer 70:1102–1110

    PubMed  Google Scholar 

  • Bunn PA, Soriano A, Helfrich BA et al. (2000) Her2/neu expression and effects of herceptin alone and in combination with cytotoxic agents in lung cancer. Proc Am Assoc Cancer Res 41:719

    Google Scholar 

  • Butz M (1999) Beruflich verursachte Krebserkrankungen-Eine Darstellung der im Zeitraum 1978 bis 1997 anerkannten Fälle. Hauptverband der gewerblichen Berufsgenossenschaften, Sankt Augustin

    Google Scholar 

  • Carbone DP (1997) The biology of the lung cancer. Semin Oncol 24:388–401

    PubMed  CAS  Google Scholar 

  • Carbone DP (1999) Molecular modalities in the treatment of lung cancer. Oncology [Suppl 5] 13:142–147

    PubMed  CAS  Google Scholar 

  • Chan DC, Soriano A, Kane MA, Helfrich B, Bunn PA (2000) Biology of lung cancer. In: Hansen H (ed) The IASLC textbook of lung cancer. Dunitz, London, pp 27–73

    Google Scholar 

  • Chiba I, Takahashi T, Nau MM et al. (1990) Mutations in the p53 gene are frequent in primary, resected non small lung cancer. Oncogene 5:1603–1606.

    PubMed  CAS  Google Scholar 

  • Chin K, Ueda K, Pastan I, Gottesman M (1992) Modulation of activity of the promotor of the human MDRI gene by ras and p53. Science 255:459–462

    PubMed  CAS  Google Scholar 

  • Chiu R, Boyle WJ, Meek J, Hunter T, Karin M (1988) The c-fos protein interacts with c-jun/AP-1 to stimulate transcription from AP-l responsive genes. Cell 54:541–542

    PubMed  CAS  Google Scholar 

  • Chung GTY, Sundaresan V, Hasleton P, Rudd R, Taylor R, Rabbitts PH (1996) Clonal evolution of lung tumors. Cancer Res 56:1609–1614

    PubMed  CAS  Google Scholar 

  • Dalquen P, Sauter G, Torhorst J et al. (1996) Nuclear p53 overexpression is an independent prognostic parameter in node-negative non-small cell lung carcinoma. J Pathol 178:53–58

    PubMed  CAS  Google Scholar 

  • Dasika GK, Lin SC, Zhao S, Sung P, Tomkinson A, Lee EY (1999) DNA damage-induced cell cyde checkpoints and DNA strand break repair in development and tumorigenesis. Oncogene 18:7883–7899

    PubMed  CAS  Google Scholar 

  • De Jong D, Prins FA, Mason DY, Reed JC, Van Ommen GB, Kluin PM (1994) Subcellular localization of the bd-2 protein in malignant and normal lymphoid cells. Cancer Res 54:256–260

    PubMed  Google Scholar 

  • Denissenko MF, Pao A, Tang M, Pfeifer GP (1996) Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53. Science 274:430–432

    PubMed  CAS  Google Scholar 

  • DePinhoo RA, Schreiber-Agus N, Alt FW (1991) Myc family oncogenes in the development of normal and neoplastic cells. Adv Cancer Res 57:1–46

    Google Scholar 

  • De Vos S, Miller CW, Takeuchi S, Gombart AF, Cho SK, Koeffler HP (1995) Alterations of CDKN2 (p16) in non-small celling cancer. Genes Chromosomes Cancer 14:164–170

    PubMed  Google Scholar 

  • Disis ML, Cheever MA (1997) HER-2/neu protein: a target for antigen-specific immuntherapy of human cancer. Adv Cancer Res 71:343–371

    PubMed  CAS  Google Scholar 

  • Dockhorn-Dworniczak B, Simon R, Brinkschmidt C, Poremba C, Böcker W (1998) Molekularbiologic maligner Tumorerkrankungen. Onkologe 4:671–681

    Google Scholar 

  • Dosaka-Akita H, Hu SX, Fujino M et al. (1997) Altered retinoblastoma protein expression in nonsmall cell lung cancer: its synergistic effects with altered ras and p53 protein status on prognosis. Cancer 79:1329–1337

    PubMed  CAS  Google Scholar 

  • Drings P (1993) Diagnostics and staging as a basis for planning therapy in lung cancer. Gen Thorac Surg 14–24

    Google Scholar 

  • Ebina M, Steinberg SM, Mulshine JL, Linnoila RI (1994) Relationship of p53 overexpression and up-regulation of proliferating cell nuclear antigen with the clinical course of non-small cell lung cancer. Cancer Res 54:2496–2503

    PubMed  CAS  Google Scholar 

  • El-Deiry WS, Tokino T, Velculescu VE et al. (1993) WAFI a potential mediator of p53 tumor suppression. Cell 75:817–825

    PubMed  CAS  Google Scholar 

  • Fidler IJ (1997) Molecular biology of cancer: invasion and metastasis. In: DeVita VT, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology. Lippincott-Raven, Philadelphia, pp 135–152

    Google Scholar 

  • Fields S, Jang S (1990) Presence of a potent transcription activating sequence in the p53 protein. Science 249:1046–1049

    PubMed  CAS  Google Scholar 

  • Fisseler-Eckhoff A, Müller K-M (1992) Early cancer and preneoplastic lesions of the lung-extracellular matrix components. In: Bernal SD, Hesketh PJ (eds) Lung cancer differentiation. Implications for diagnosis and treatment. Dekker, New York, pp 78–89

    Google Scholar 

  • Fisseler-Eckhoff A, Müller K-M (1994) Pathologic der Pulmonalarterien bei Lungentumoren. Dtsch Med Wochenschr119:1415–1420

    PubMed  CAS  Google Scholar 

  • Fong KM, Sekido Y, Minna JD (1999) Molecular pathogenesis of lung cancer. J Thorac Cardiovasc Surg 118:1136–1152

    PubMed  CAS  Google Scholar 

  • Fontanini G, Bigini D, Vignati S et al. (1995a) Microvessel count predicts metastatic disease and survival in nonsmall cell lung cancer. J Pathol 177:57–63

    PubMed  CAS  Google Scholar 

  • Fontanini G, Vignati S, Bigini D et al. (1995b) Bd-2 protein: a prognostic factor inversely correlated to p53 in nonsmall-cell lung cancer. Br J Cancer 71:1003–1007

    PubMed Central  PubMed  CAS  Google Scholar 

  • Frederiksen KS, Petri A, Abrahamsen N, Poulsen HS (1999) Gene therapy for lung cancer. Lung Cancer 23:191–207

    PubMed  CAS  Google Scholar 

  • Freedman DA, Levine AJ (1999) Regulation of the p53 protein by the MDM2 oncoprotein-Thirtyeight G. H. A. Clowes Memorial Award Lecture. Cancer Res 59:1–7

    PubMed  CAS  Google Scholar 

  • Friend SH, Bernards R, Rogelj S et al. (1986) A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 323:643–645

    PubMed  CAS  Google Scholar 

  • Garziano SL, Cowan BY, Carney DN et al. (1987) Small cell lung cancer line derived from a primary tumor with a characteristic deletion of 3p. Cancer Res 48:2141–2155

    Google Scholar 

  • Gazdar AF (1994) The molecular and cellular basis of human lung cancer. Anticancer Res 14:261–267

    PubMed  CAS  Google Scholar 

  • Gazdar AF, Carney DN, Nau MM, Minna JD (1985) Characterization of variant subdasses of cell line derived from small cell lung cancer having distinct biochemical, morphological and growth properties. Cancer Res 45:2924–2930

    PubMed  CAS  Google Scholar 

  • Geddes DM (1979) The natural history of lung cancer: a review based on rates of tumor growth. Br J Dis Chest 73:1–17

    PubMed  CAS  Google Scholar 

  • Giaccone G (1996) Oncogenes and antioncogenes in lung tumorigenesis. Chest 109:130S–134S

    PubMed  CAS  Google Scholar 

  • Gonzales S, Basewitz DB von, Grundmann E, Nakhosteen JA, Müller K-M (1986) The ultrastructural heterogeneity of potentially preneoplastic lesions in the human bronchial mucosa. Pathol Res Pract 181:408–417

    Google Scholar 

  • Greenblatt MS, Bennett WP, Hollstein M, Harris CC (1994) Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54:4855–4878

    PubMed  CAS  Google Scholar 

  • Griffin CA, Baylin SB (1985) Expression of the c-myb oncogene in human small cell lung carcinoma. Cancer Res 45:272–275

    PubMed  CAS  Google Scholar 

  • Hajj C, Akoum R, Bradley E, Paquin F, Ayoub J (1990) DNA alterations at proto oncogene loci and their clinical significance in operable non small cell lung cancer. Cancer 66:733–739

    PubMed  CAS  Google Scholar 

  • Harbour JW, Lai SI, Whang-Peng J, Gazdar AF, Minna JD, Kaye FJ (1988) Abnormalities in structure and expression of the retinoblastoma gene in SCLC. Science 241:353–357

    PubMed  CAS  Google Scholar 

  • Hasimoto T, Tokuchi Y, Hayashi M et al. (1999) p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas. Cancer Res 59:5572–5577

    Google Scholar 

  • Haugen A (2000) Etiology of lung cancer. In: Hansen H (ed) The IASLC textbook of lung cancer. Dunitz, London, pp 1–12

    Google Scholar 

  • Hermanek P, Hutter RVP, Sobin LH, Wittekind C (1999) Classification of isolated tumor cells and micrometastasis. Cancer 86:2668–2673

    PubMed  CAS  Google Scholar 

  • Higashiyama M, Doi O, Kodama K, Yokouchi H, Tateishi R (1994) Retinoblastoma protein expression in lung cancer: an immunohistochemical analysis. Oncology 51:544–551

    PubMed  CAS  Google Scholar 

  • Higashiyama M, Doi O, Kodama K, Yokouchi H, Tateishi R (1995) High prevalence of bcl-2 oncoprotein expression in small cell lung cancer. Anticancer Res 15:503–505

    PubMed  CAS  Google Scholar 

  • Higashiyama M, Doi O, Kodama K et al. (1997) MDM2 gene amplification and expression in non-small-cell lung cancer: immunohistochemical expression of its protein is a favourable prognostic marker in patients without p53 protein accumulation. Br J Cancer 75:1302–1308

    PubMed Central  PubMed  CAS  Google Scholar 

  • Hirsch FR, Matthews MI, Aisner S et al. (1988) Histopathologic classification of small cell lung cancer.Changing concepts and terminology. Cancer 62:973–977

    PubMed  CAS  Google Scholar 

  • Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ (1990) Bcl-2 is an inner mitochondrial membrane proteine that blocks programmed cell death. Nature 348:334–336

    PubMed  CAS  Google Scholar 

  • Hollstein M, Sidransky D, Vogelstein B, Harris CC (1991) p53 mutations in human cancer. Science 253:362–366

    Google Scholar 

  • Hollstein M, Shomer B, Greenblatt M et al. (1996) Somatic point mutations in the p53 gene of human tumors and cell lines. Updated compilation. Nucleic Acids Res 24:141–146

    CAS  Google Scholar 

  • Hollstein M, Bartsch H, Wesch H et al. (1997a) p53 gene mutation analysis in tumors of patients exposed to a-particles. Carcinogenesis 18:511–516

    PubMed  CAS  Google Scholar 

  • Hollstein M, Soussi T, Thomas G, Brevern M-C von, Bartsch H (1997b) P53 gene alterations in human tumors: perspectives for cancer control. Rec Results Cancer Res 143:370–389

    Google Scholar 

  • Horio Y, Takahashi,Kuroishi T et al. (1993) Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer. Cancer Res 53:1–4

    PubMed  CAS  Google Scholar 

  • Horowitz JM, Park SH, Bogenmann E et al. (1990) Frequent inactivation of the retinoblastoma anti-oncogene is restricted to a subset of human tumor cells. Proc Natl Acad Sci USA 87:2775–2779

    PubMed Central  PubMed  CAS  Google Scholar 

  • Höfler H (1997) Spektrum neuro endokriner Tumoren der Lunge. Pathologe 18:322–323

    Google Scholar 

  • Husgafvel-Pursiainen K, Hackman P, Ridanpaa M et al. (1993) K-ras mutations in human adenocarcinoma of the lung-association with smoking and occupational exposure to asbestos. Int J Cancer 53:250–256

    PubMed  CAS  Google Scholar 

  • Hussain SP, Harris CC (1998) Molecular epidemiology of human cancer: contribution of mutation spectra studies of tumor suppressor genes. Cancer Res 58:4023–4037

    PubMed  CAS  Google Scholar 

  • Iggo R, Gatter K, Bartek J, Lane DP, Harris AL (1990) Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 355:675–679

    Google Scholar 

  • Janus F, Albrechtsen N, Dornreiter I, Wies müller L, Grosse F, Deppert W (1999) The dual role model for p53 in maintaining genomie integrity. Cell Mol Life Sci 55:12–27

    PubMed  CAS  Google Scholar 

  • Johnson B, Ihde D, Makuch RW et al. (1987) Myc family oncogene amplification in tumor cell lines established from small cell lung cancer patients and its relationship to clinical status and course. J Clin Invest 79:1629–1634

    PubMed Central  PubMed  CAS  Google Scholar 

  • Junker K, Müller K-M (1989) Metastasierungsmuster beim Bronchialkarzinom. Z Herz Thorax Gefäßchir 3:189–194

    Google Scholar 

  • Junker K, Krapp D, Müller K-M (1995) Kleinzelliges Bronchialkarzinom nach ChemoTherapic. Pathologe 16:217–222

    PubMed  CAS  Google Scholar 

  • Junker K, Thomas M, Schulmann K, Klinke F, Bosse U, Müller K-M (1997a) Tumor regression in non-small cell lung cancer following neoadjuvant therapy-histological assessment. J Cancer Res Clin Oncol 123:469–477

    PubMed  CAS  Google Scholar 

  • Junker K, Thomas M, Schulmann K, Klinke V, Bosse U, Müller K-M (1997b) Regressionsgrading neoadjuvant behandelter niehtkleinzelliger Lungentumoren. Pathologe 18: 131–140

    PubMed  CAS  Google Scholar 

  • Kamp A, Gruis NA, Weaver-Feldhaus J et al. (1994) A cell cycle regulator potentially involved in genesis of many tumor types. Science 264:436–440

    Google Scholar 

  • Kaufmann O, Dietel M (2000) Thyroid transcription factor-1 is the superior immunohistochemical marker for pulmonary adenocarcinomas and large cell carcinomas compared to surfactant proteins A and B. Histopathology 36:8–16

    PubMed  CAS  Google Scholar 

  • Kern JA, Torney L, Nordberg JE, Weiner DB, Greene MI, Robinson RA (1990) p185neu expression in lung adenocarcinomas predicts shortened survival. Cancer Res 50:5184–5191

    PubMed  CAS  Google Scholar 

  • Kern JA, Robinson RA, Gazdar A, Torney L, Weiner DB (1992) Mechanisms of p185HER2 expression in human non-small cell lung cancer cell lines. Am J Respir Cell Mol Biol 6:359–363

    PubMed  CAS  Google Scholar 

  • Kiefer PE, Bepler G, Kubasch M, Havemann K (1987) Amplification and expression of protooncogenes in human small cell lung cancer cell lines. Cancer Res 47:6236–6242

    PubMed  CAS  Google Scholar 

  • Kikuchi M (1999) Retropharyngeal rhabdomyosarcoma mimicking pseudotumor cerebri. Pediatr Neurol 21:496–499

    PubMed  CAS  Google Scholar 

  • Knudson AG JR (1971) Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 68:820–823

    PubMed Central  PubMed  Google Scholar 

  • Koechli OR, Schaer GN, Scifert B et al. (1994) Mutant p53 protein associated with chemosensitivity in breast cancer specimens. Lancet 344: 1647–1648

    PubMed  CAS  Google Scholar 

  • Kok K, Osinga J, Carritt B et al. (1987) Deletion of a DNA sequence at the chromosomal region 3p21 in all major types of lung cancer. Nature 330:578–581

    PubMed  CAS  Google Scholar 

  • Krajewski S, Tanaka S, Takayama S, Schibier M, Fenton W, Reed JC (1993) Investigation of the subcellular distribution of the bcl-2 oncoprotein: residence in the nuclear envelope, endoplasmatic reticulum, and outer mitochondrial membrane. Cancer Res 53:4701–47l4

    PubMed  CAS  Google Scholar 

  • Kreuzer M, Kreienbrock L, Gerken M et al. (1998) Risk factors for lung cancer in young adults. Am J Epidemiol 147:1028–1037

    PubMed  CAS  Google Scholar 

  • Kreuzer M, Müller K-M, Gerken M, Wiehmann H-E (1999) Lung cancer histologie types and age of onset. Cancer 85: 1958–1965

    PubMed  CAS  Google Scholar 

  • Kwiatkowski DJ, Harpole DH, Godleski J et al. (1998) Molecular pathologic substaging in 244 stage I non-small cell lung cancer patients. J Clin Oncol 16:2468–2477

    PubMed  CAS  Google Scholar 

  • Lakin ND, Jackson SP (1999) Regulation of p53 in response to DNA damage. Oncogene 18:7644–7655

    PubMed  CAS  Google Scholar 

  • Leach FS, Tokino T, Meltzer P et al. (1993) p53 Mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res 53:2231–2234

    PubMed  CAS  Google Scholar 

  • Lee W, Mitchell P, Tjian R (1987) Purified transcription factor AP-l interacts with TPA-indueible elements. Cell 49:741–752

    PubMed  CAS  Google Scholar 

  • Levine AJ, Chang AW, Dittmer D et al. (1994a) The p53 tumor suppressor gene. J Lab Clin Med 123:817–823

    PubMed  CAS  Google Scholar 

  • Levine AJ, Perry ME, Chang A, Silver A, Dittmer D, Wu M (1994b) The 1993 Walter Hubert Lecture-the role of the p53 tumour suppressor gene in tumorigenesis. Br J Cancer 69:409–416

    PubMed Central  PubMed  CAS  Google Scholar 

  • Lichtenstein P, Holm NV, Verkasalo PK et al. (2000) Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 343:78–85

    PubMed  CAS  Google Scholar 

  • Little CD, Nau MM, Carney DN, Gazdar AF, Minna JD (1983) Amplification and expression of the c-myc oncogene in human lung cancer cell lines. Nature 306:194–196

    PubMed  CAS  Google Scholar 

  • Lotem J, Sachs L (1993) Regulation by bcl-2, c-myc, and p53 of susceptibility to induction of apoptosis by heat shock and cancer chemotherapy compounds in differentiation competent and differentiation-defective myeloid leukemic cells. Cell Growth Differ 4:41–47

    PubMed  CAS  Google Scholar 

  • Lubin R, Zalcman G, Bouchet L et al. (1995) Serum p53 antibodies as early markers of lung cancer. Nat Med1:701–702

    PubMed  CAS  Google Scholar 

  • Mannino DM, Ford E, Giovanni GA, Thun M (1998) Lung cancer deaths in the United States from 1979 to 1992: an analysis using multiple-cause mortality data. Int J Epidemiol 27:159–166

    PubMed  CAS  Google Scholar 

  • Marchetti A, Doglioni C, Barbareschi M et al. (1996) p21 RNA and protein expression in non-small cell lung carcinomas: evidence of p53-independent expression and associatiOn with tumoral differentiation. Oncogene 12:1319–1324

    PubMed  CAS  Google Scholar 

  • May P, May E (1999) Twenty years of p53 research: structural and functional aspects of the p53 protein [published erratum appears in Oncogene 2000 23:1734]. Oncogene 18:7621–7636

    PubMed  CAS  Google Scholar 

  • McDowell EM (1987) Bronchogenie carcinomas. In: McDoweil EM (ed) Current problems in tumor pathology, lung carcinomas. Churchill Livingstone, Harlow, pp 255–285

    Google Scholar 

  • McLaren R, Kuzu I, Dunnill M, Harris CC, Lane DP, Gatter KC (1992) The relationship of p53 immunostaining to survival in carcinoma of the lung. Br J Cancer 66:735–738

    PubMed Central  PubMed  CAS  Google Scholar 

  • Mitsudomi T, Viallet J, Mulshine J, Linnoila R, Minna JD, Gazdar AF (1991) Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines. Oncogene 6: 1353–1362

    PubMed  CAS  Google Scholar 

  • Miwa W, Yasuda J, Yashima K, Makino R, Sekiya T (1994) Absence of activating mutations of the rRAF1 protooncogene in human lung cancer. Biol Chem 375:705–709

    CAS  Google Scholar 

  • Miyashita T, Reed JC (1995) Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80:293–299

    PubMed  CAS  Google Scholar 

  • Miyashita T, Krajewski S, Krajewska M, Reed J (1994) Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9:1799–1805

    PubMed  CAS  Google Scholar 

  • Momand J, Zambetti G, Olson D, Levine A (1992) The mdm2 oncogene product forms a complex with the p53 protein and inhibits p53 mediated transactivation. Cell 69:1237–1245

    PubMed  CAS  Google Scholar 

  • Mountain CF (1986) A new international staging-system for lung cancer. Chest [Suppl] 98:225–232

    Google Scholar 

  • Mountain CF (1996) Lung cancer staging: 1997 revisions. In: Antypas G (ed) 2nd International Congress on Lung Cancer. Monduzzi, Bologna, pp 11–13

    Google Scholar 

  • Mountain CF (1997) Revisions in the international system for staging lung cancer. Chest 111: 1710–1717

    PubMed  CAS  Google Scholar 

  • Müller K-M (1988) Early cancer of the lung. Recent Results Cancer Res 106:119–130

    PubMed  Google Scholar 

  • Müller K-M (1999) Neues zur Pathologie der Lungentumoren. Verh Dtsch Ges Pathol 83:168–183

    PubMed  Google Scholar 

  • Müller K-M, Fisseler-Eckhoff A (1998) Pathologie der Lungentumoren. In: Drings P, Vogt-Moykopf I (Hrsg) Thoraxtumoren: Diagnostik-Staging-gegenwärtiges Therapickonzept, 2. Aufl. Springer, Berlin Heidelberg New York, S 3–34

    Google Scholar 

  • Müller K-M, Menne R (1985) Small cell carcinoma of the lung: pathological anatomy. Recent Results Cancer Res 97:11–24

    PubMed  Google Scholar 

  • Müller K-M, Brämer UG, Hiddemann W (1986) Probleme der morphologischen Klassifikation bösartiger Lungentumoren. Atemw Lungenkrkh 12:459–465

    Google Scholar 

  • Müller K-M, Fisseler-Eckhoff A, Reitemeyer E (1988) Stromareaktionen in Lungentumoren-Tumorvernarbung und sogenanntes Narbenkarzinom. Fortsehr Med 106:19–24

    Google Scholar 

  • Müller K-M, Junker K, Stief A (1993) Wert und Bedeutung pathologisch-anatomischer Befunde für die Thoraxchirurgie. In: Vogt-Moykopf I, Drings P (Hrsg) Thoraxchirurgie-Stand und Ausbliek. Steinkopff, Darmstadt, S 23–35

    Google Scholar 

  • Müller K-M, Junker K, Wiethege Th (1995) Niehtkleinzellige Lungentumoren-Morphologie, Tumorregression, Molekularpathologie. Onkologe 1:429–440

    Google Scholar 

  • Müller K-M, Wiethege Th, Junker K (1998) Pathologie kleinzelliger Lungentumoren. Onkologe 4:996–1004

    Google Scholar 

  • Noble J, Willetts K, Mercer W, Reddel R (1992) Effects of exogenous wild-type p53 on a human lung carcinoma cell line with endogenous wild-type p53. Exp Cell Res 203:297–304

    PubMed  CAS  Google Scholar 

  • Nobori T, Miura K, Wu D, Carson D (1994) Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368:753–756

    PubMed  CAS  Google Scholar 

  • Nuorva K, Soini Y, Kamel D et al. (1993) Concurrent p53 expression in bronchial dysplasias and squamous cell lung carcinomas. Am J Pathol 142:725–732

    PubMed Central  PubMed  CAS  Google Scholar 

  • Ohsaki Y, Toyoshima E, Fujiuchi S et al. (1996) Bcl-2 and p53 protein expression in non-small cell lung cancers: correlation with survival time. Clin Cancer Res 2:915–920

    PubMed  CAS  Google Scholar 

  • Okamoto A, Hussain SP, Hagiwara K et al. (1995) Mutations in the p16(INK4)/MTS1/CDKN2, pI5(INK4B)/MTS2, and p18 genes in primary and metastatic lung cancer. Cancer Res 55:1448–1451

    PubMed  CAS  Google Scholar 

  • Oren M, Rotter V (1999) p53-the first twenty years. Cell Mol Life Sci 55:9–11

    PubMed  CAS  Google Scholar 

  • Pantel K, Knebel-Boeberitz MV, Izbicki JR, Riethmüller G (1997) Disseminierte Tumorzellen: Diagnostik, prognostische Relevanz, Phänotypisierung und therapeutische Strategien. Chirurg 67:1241–1250

    Google Scholar 

  • Pappai G, Pöhl CD (1999) Uranerzbergbau und Berufsgenossenschaften: Das Berufskrankheitengeschehen der ehemaligen Wismut-Beschäftigten. BG 110:596–602

    Google Scholar 

  • Petersen I, Langreck H, Wolf G et al. (1996) Small cell lung cancer is characterized by a high incidence of deletions on chromosomes 3p, 4q, 5q, 1Oq, 13q, and 17p. Br J Cancer 75:79–86

    Google Scholar 

  • Petersen I, Bujard M, Petersen S et al. (1997) Patterns of chromosomal imbalances in adenocarcinoma and squamous cell carcinoma of the lung. Cancer Res 57:2331–2335

    PubMed  CAS  Google Scholar 

  • Petit AM, Rak J, Hung MC et al. (1997) Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 151:1523–1530

    PubMed Central  PubMed  CAS  Google Scholar 

  • Pezzella F, Turley H, Kuzu I et al. (1993) Bcl-2 protein in non-small-cell lung carcinoma. N Engl J Med 329:690–694

    PubMed  CAS  Google Scholar 

  • Pohlabeln H, Jöckel K, Müller K-M (1997) The relation between various histological types of lung cancer and the number of years since cessation of smoking. Lung Cancer 18:223–229

    PubMed  CAS  Google Scholar 

  • Quinlan DC, Davidson A, Summers C, Warden H, Doshi H (1992) Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res 52:4828–4831

    PubMed  CAS  Google Scholar 

  • Quintinilla M, Bron K, Ramsden N, Balmain A (1986) Carcinogen-specific mutation and amplification of H-ras during mouse skin carcinogenesis. Nature 322:78–80

    Google Scholar 

  • Rachwal WJ, Bongiorno PF, Orringer MB, Whyte RI, Ethier SP, Beer DG (1995) Expression and activation of erbB-2 and epidermal growth factor receptor in lung adenocarcinomas. Br J Cancer 72:56–64

    PubMed Central  PubMed  CAS  Google Scholar 

  • Rak J, Mitsuhashi Y, Bayko L et al. (1995) Mutant ras oncogenes upregulate VEGFJVPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res 55:4575–4580

    PubMed  CAS  Google Scholar 

  • Ransonne LJ, Verma IM (1990) Nuclear oncogenes fos and jun. Annu Rev Cell Biol 6:539–557

    Google Scholar 

  • Raycroft L, Wu HY, Lozano G (1990) Transcriptional activation by wild type but not transforming mutants of the p53 anti oncogene. Science 249:1049–1051

    PubMed Central  PubMed  CAS  Google Scholar 

  • Reissmann PT, Koga H, Takahashi R et al. (1993) Inactivation of the retinoblastoma susceptibility gene in nonsmall-cell lung cancer. The Lung Cancer Study Group. Oncogene 8:1913–1919

    PubMed  CAS  Google Scholar 

  • Rodenhuis S, Van de Wetering ML, Mooi WJ, Evers S, Zandwijk N van, Bos JL (1987) Mutational activation of the kras oncogene: a possible pathogenic factor in adenocarcinoma of the lung. N Engl J Med 317:929–935

    PubMed  CAS  Google Scholar 

  • Rodenhuis S, Siebos RJC, Boot AJ et al. (1988) Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung. Cancer Res 48:5738–5741

    PubMed  CAS  Google Scholar 

  • Rosell R, Gomez-Codina J, Camps C et al. (1994) A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 330:153–158

    PubMed  CAS  Google Scholar 

  • Roth JA (1995) Molecular events in lung cancer. Lung Cancer 12:S3–S15

    PubMed  Google Scholar 

  • Roth JA, Fossella F, Komaki R et al. (1994) A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Nat Cancer Inst 86:673–680

    PubMed  CAS  Google Scholar 

  • Rusch V, Klimstra D, Venkatraman E et al. (1995) Aberrant p53 expression predicts clinical resistance to cisplatinbased chemotherapy in locally advanced non-small cell lung cancer. Cancer Res 55:5038–5042

    PubMed  CAS  Google Scholar 

  • Rygaard K, Nakamura T, Sang-Thomsen M (1993) Expression of the proto-oncogenes c-met and c-kit and their ligands, hepatocyte growth factor/scatter factor and stern cell factor, in SCLC cell lines and xenografts. Br J Cancer 67:37–46

    PubMed Central  PubMed  CAS  Google Scholar 

  • Schirren CI (1996) Die systematische mediastinale Lymphknotendissektion beim Bronchialkarzinom-Indikation, Technik und Ergebnisse. Habilitationsschrift, RuprechtKarl-Universität Heidelberg

    Google Scholar 

  • Schmitz I, Fisseler-Eckhoff A, Erfkamp S, Twent U, Müller K-M, Becker H (1994) Characterization of cytokeratin expression in squamous cell carcinoma of the lung-immunohistochemical and electronmicroscopical investigations. In: Antypas G (ed) International Congress for Lung Cancer. Monduzzi, Bologna, S 123–127

    Google Scholar 

  • Schraufnagel DE (1990) Electron microscopy of the lung. Dekker, New York

    Google Scholar 

  • Schuette J, Nau M, Birrer M, Thomas F, Gazdar AF, Minna JD (1988) Constitutive expression of multiple mRNA forms of the c-jun oncogene in human lung cancer cell lines. Proc Am Assoc Cancer Res 29:455

    Google Scholar 

  • Sekido Y, Obata Y, Ueda R et al. (1991) Preferential expression of c-kit protooncogene transscripts in small cell lung cancer. Cancer Res 51:2416–2419

    PubMed  CAS  Google Scholar 

  • Selter H, Montenarh M (1994) The emerging picture of p53. Int Arch Occup Environ Health 26:145–154

    CAS  Google Scholar 

  • Selter H, Amela-Neuschwander S, Villena-Heinsen C, Montenarh M (1995) Antibodies against murine double minute-2 (mdm2) in sera of patients with various gynaecological diseases. Cancer Lett 96: 111–115

    PubMed  CAS  Google Scholar 

  • Shapiro GI, Edward CD, Kobzik L et al. (1995) Reciprocal Rb inactivation and p16(INK4) expression in primary lung cancers and cell lines. Cancer Res 55:505–509

    PubMed  CAS  Google Scholar 

  • Shew JY, Chen PL, Bookstein R, Lee EY (1990) Deletion of a splice donor site ablates expression of the following exons and produces an unphosphorylated RB protein unable to bind SV40 T antigen. Cell Growth Differ 1:17–25

    PubMed  CAS  Google Scholar 

  • Shimizu E, Coxon A, Otterson GA et al. (1994) RB protein status and clinical correlation from 171 cell lines representing lung cancer, extrapulmonary small cell carcinoma, and mesothelioma. Oncogene 9:2441–2448

    PubMed  CAS  Google Scholar 

  • Shows TB, McAlpine PJ, Boucher C et al. (1987) Guidelines for human gene nomenclature. An international system for human gene nomenclature (ISGN, 1987). Cytogenet Cell Genet 46:11–28

    PubMed  CAS  Google Scholar 

  • Siegfried JM, Davis AJ, Gubish CT et al. (1998) Growth factors and recepetors in non-small cell lung cancer. In: Kane MA, Bunn PA (eds) Biology of lung cancer. Dekker, New York, S 317–336

    Google Scholar 

  • Slamon DJ, Godolphin W, Jones LA et al. (1989) Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science 244:707–712

    PubMed  CAS  Google Scholar 

  • Slamon DJ, Leyland-Jones B, Shak S et al. (1998) Addition of herceptin (humanized anti Her2 antibody) to first line chemotherapy for Her2 overexpressing metastatic breast cancer markedly increases antieancer activity: a randomized multinational controlled phase III trials. Proc Am Soc Clin Onco117:98a

    Google Scholar 

  • Siebos RJ, Kibbelaar RE, Dalesio O et al. (1990) K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 323:561–565

    Google Scholar 

  • Soini Y, Kamel D, Nuorva K, Lane DP, Vähäkangas K, Pääkko P (1992) Low p53 protein expression in salivary gland tumours compared with lung carcinomas. Virchows Arch 421:415–420

    CAS  Google Scholar 

  • Soussi T (2000) p53 antibodies in the sera of patients with various types of cancer: a review. Cancer Res 60:1777–1788

    PubMed  CAS  Google Scholar 

  • Sozzi G, Veronese ML, Negrini M et al. (1996) The FHIT gene 3p14.2 is abnormal in lung cancer. Cell 85:17–26

    PubMed  CAS  Google Scholar 

  • Sugio K, Kishimoto Y, Virmani AK, Hung JY, Gazdar AF (1994) K-ras mutations are a relatively late event in the pathogenesis of lung carcinomas. Cancer Res 54:5811–5815

    PubMed  CAS  Google Scholar 

  • Szabo E, Riffe ME, Steinberg SM, Birrer MJ, Linnoila RI (1996) Altered cJUN expression: an early event in human lung careinogenesis. Cancer Res 56:305–315

    PubMed  CAS  Google Scholar 

  • Taylor JA, Watson MA, Devereux TR, Michels RY, Saccomanno G, Anderson M (1994) P53 mutation hotspot in radon-associated lung cancer. Lancet 343:86–87

    PubMed  CAS  Google Scholar 

  • Thomas M, Rübe C, Semik M et al. (1999) Impact of preoperative bimodality induction including twice-daily-radiation on tumor regression and survival in stage III non-small-cell lung cancer. J Clin Oncol 17:1185–1193

    PubMed  CAS  Google Scholar 

  • Thottassery JV, Zambetti GP, Arimori K, Schuetz EG, Schuetz JD (1997) p53-dependent regulation of MDRI gene expression causes selective resistance to chemotherapeutic agents. Proc Natl Acad Sci USA 94:11037–11042

    PubMed Central  PubMed  CAS  Google Scholar 

  • Travis WD, Colby TV, Corrin B, Shimosato Y, Brambilla E, collaborators from 14 countries (1999) histological typing of lung and pleural tumors, 3rd edn. Springer, Berlin Heidelberg New York

    Google Scholar 

  • True LD (1990) Atlas of diagnostic immunohistopathology. Lippincott, Philadelphia

    Google Scholar 

  • Tseng JE, Rodriguez M, Ro J, Liu D, Hong WK, Mao L (1999) Gender differences in pS3 mutational status in small cell lung cancer. Cancer Res 59:5666–5670

    PubMed  CAS  Google Scholar 

  • Tsujimoto Y, Cossman J, Jaffe E, Croce CM (1985) Involvement of the bcl-2 gene in human follicular lymphoma. Science 228:1440–1443

    PubMed  CAS  Google Scholar 

  • Vähäkangas KH, Samet JM, Lane DP, Harris CC et al. (1992) Mutations of p53 and ras gene in radon associated lung cancer from uranium miners. Lancet 339:576–580

    PubMed  Google Scholar 

  • Volm M, Efferth T, Mattem J (1992) Oncoprotein (c-myc, cerbB1, c-erbB2, c-fos) and suppressor gene products (p53) gene expression in squamous cell carcinomas of the lung. Clinical and biological correlations. Anticancer Res 12:11–20

    PubMed  CAS  Google Scholar 

  • Volm M, Drings P, Mattem J, Wodrieh W (1993a) Prognostic value of oncoproteins for the survival of patients with non-small cell lung carcinomas. Int J Cancer 2:767–772

    CAS  Google Scholar 

  • Volm M, Drings P, Wodrieh W (1993b) prognostic significance of the expression of c-fos, c-jun and erbB-1 oncogene products in human squamous cell lung carcinomas. J Cancer Res Clin Oncol 119:507–510

    PubMed  CAS  Google Scholar 

  • Volm M, Vogt-Moykopf I, Wodrieh W (1993c) C-K-ras and c-N-ras are important and stage-independent prognostic indicators in adenocarcinomas of the lung. Cancer J Sci Am 6:37–42

    Google Scholar 

  • Walker C, Robertson L, Myskow M, Dixon G (1995) Expression of the BCL-2 protein in normal and dysplastic bronchial epithelium and in lung carcinomas. Br J Cancer72:164–169

    PubMed Central  PubMed  CAS  Google Scholar 

  • Wallace-Brodeur RR, Lowe SW (1999) Clinical implications of p53 mutations. Cell Mol Life Sci 55:64–75

    PubMed  CAS  Google Scholar 

  • Weidner N (1995) Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol 147:9–19

    PubMed Central  PubMed  CAS  Google Scholar 

  • Wen D, Peles E, Cuppies R et al. (1992) Neu differentiation factor: a transmembrane glycoprotein containing an EGF domain and an immunoglobulin ho molo gy unit. Cell 69:559–572

    PubMed  CAS  Google Scholar 

  • Whang-Peng J, Kao-Shan CS, Lee EC et al. (1982) Specific chromosome defects associated with human small-cell lung cancer; deletion 3p(14-23). Science 215:181–182

    PubMed  CAS  Google Scholar 

  • Wiethege Th, Voss B, Müller K-M (1994) Immunhistochemische Untersuchungen zur Akkumulation des TumorSuppressor-Gens p53 in Bronchialkarzinomen. Atemw Lungenkrkh 20:326–328

    Google Scholar 

  • World Health Organization (1981) International histological classification of tumours No. 1, 2nd edn. World Health Organization, Geneva

    Google Scholar 

  • World Health Organization (1982) The World Health Organization histologic al typing of lung tumours-2nd edn.Am J Clin Pathol 77:123–136

    Google Scholar 

  • Wu GS, Eldeiry WS (1996) P53 and chemosensitivity. Nat Med 2:255–256

    PubMed  CAS  Google Scholar 

  • Xiao S, Li D, Corson J, Vijg J, Fleteher JA (1995) Codeletion of pl5 and pl6 genes in primary non-small cell lung cancer. Cancer Res 55:2968–2971

    PubMed  CAS  Google Scholar 

  • Xu H, Cagle P, Hu S et al. (1995) Altered retinoblastoma (RB) and p53 protein status as a synergistie prognostic factor in non-small cell lung carcinoma. Proc Am Assoc Cancer Res 36:246

    Google Scholar 

  • Yang Q, Wesch H, Müller K-M, Bartsch H, Wegener K, Hollstein M (1999) Analysis of radon-associated squamous cell carcinomas of the lung for a p53 gene hot spot mutation. Br J Cancer 82:763–766

    Google Scholar 

  • Yap DB, Hsieh JK, Chan FS, Lu X (1999) mdm2: a bridge over the two tumour suppressors, p53 and Rb. Oncogene 18:7681–7689

    PubMed  CAS  Google Scholar 

  • Yokota J, Wada M, Shimosato Y, Terada M, Sugimura T (1987) Loss of heterozygosity on chromosomes 3, 13, and 17 in small ceH carcinoma and on chromosome 3 in adenocarcinoma of the lung. Proc Natl Acad Sci USA 84:9252–9256

    PubMed Central  PubMed  CAS  Google Scholar 

  • Yokota J, Shimosato Y, Sugimura T, Terada M (1988) Altered expression of the retinoblastoma (RB) gene in small cell carcinoma of the lung. Oncogene 3:471–475

    PubMed  CAS  Google Scholar 

  • You H, Candrian U, Maronpot RR, Stoner GD, Anderson MW (2000) Activation of Ki-ras protooncogene in spontaneously occurring and chemically induced lung tumors of strain A mouse. Proc Natl Acad Sci USA 86:3070–3074

    Google Scholar 

  • Zangemeister-Wittke U, Stahel RA (1999) Novel approaches to the treatment of small-cell lung cancer. Cell Mol Life Sci 55:1585–1598

    PubMed  CAS  Google Scholar 

  • Babcock TL, Powell DH, Bothwell RS (1976) Radiation-induced peritoneal mesothelioma. J Surg Oncol 8:369–372

    PubMed  CAS  Google Scholar 

  • Balsara BR, Bell DW, Sonoda G et al. (1999) Comparative genomic hybridization and loss of heterozygosity analyses identify a common region of deletion at 15q 11.1-15 in human malignant mesothelioma. Cancer Res 59:450–454

    PubMed  CAS  Google Scholar 

  • Baris I, Artvinli M, Sahin AA (1979) Environmental mesothelioma in Turkey. Ann N Y Acad Sci 330:432

    Google Scholar 

  • Baris I, Simonato L, Artvinli M et al. (1987) Epidemiological and environmental evidence of the health effects of exposure to erionite fibres: a four-year study of the Cappadoeian region of Turkey. Int J Cancer 39:10–17

    PubMed  CAS  Google Scholar 

  • Battifora H, McCaughey WTE (1995) Tumors of the serosal membran es, 3rd edn. Armed Forces Institute of Pathology, Washington, DC

    Google Scholar 

  • Beer TW, Buchanan R, Matthews AW, Stradling R, Pullinger N, Pethybridge RJ (1998) Prognosis in malignant mesothelioma related to MIB 1 proliferation index and histological subtype. Hum Pathol 29:246–251

    PubMed  CAS  Google Scholar 

  • Bell DW, Jhanwar SC, Testa JR (1997) Multiple regions of allelic loss from chromosome arm 6q in malignant mesothelioma. Cancer Res 57:4057–4062

    PubMed  CAS  Google Scholar 

  • Berman JJ, Rice JM (1979) Mesotheliomas and proliferative lesions of the testicular mesothelium in Fischer, SpragueDawley and Buffalo rats by methyl(acetoxymethyl)-nitrosamine (DMN-OAc). Vet Pathol 16:574–582

    PubMed  CAS  Google Scholar 

  • Bermudez E, Everitt J, Walker C (1990) Expression of growth factor and growth factor receptor RNA in rat pleural mesothelial cells in culture. Exp Cell Res 190:91–98

    PubMed  CAS  Google Scholar 

  • Bianchi C, Brollo A, Zuch C (1993) Asbestos-related familial mesothelioma. Eur J Cancer Prev 2:247–250

    PubMed  CAS  Google Scholar 

  • Bianchi AB, Mitsunaga SI, Cheng JQ et al. (1995) High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. Proc Natl Acad Sci USA 92:10854–10858

    PubMed Central  PubMed  CAS  Google Scholar 

  • Bjorkqvist AM, Tammilehto L, Anttila S, Mattson K, Knuutila S (1997) Recurrent DNA copy number changes in 1q, 4q, 6q, 9p, 13q, 14q and 22q detected by comparative genomic hybridization in malignant mesothelioma. Br J Cancer 75:523–527

    PubMed Central  PubMed  CAS  Google Scholar 

  • Bjorkqvist AM, Tammilehto L, Nordling S et al. (1998) Comparison of DNA copy number changes in malignant mesothelioma, adenocarcinoma and large-cell anaplastic carcinoma of the lung. Br J Cancer 77:260–269

    PubMed  CAS  Google Scholar 

  • Bjorkqvist AM, Wolf M, Nordling S et al. (1999) Deletions at 14q in malignant mesothelioma detected by microsatellite marker analysis. Br J Cancer 81:1111–1115

    PubMed Central  PubMed  CAS  Google Scholar 

  • Bonn D (1999) Mesothelioma deaths may double within 20 years. Lancet 353:383

    Google Scholar 

  • Boutin C, Rey F, Viallat JR (1995) Prevention of malignant see ding after invasive diagnostic procedures in patients with pleural mesothelioma: a randomized trial of local radiotherapy. Chest 108:754–758

    PubMed  CAS  Google Scholar 

  • Brenner J, Sordillo PP, Magill GB, Golbey RB (1982) Malignant mesothelioma of the pleura: review of 123 patients. Cancer 49:2431–2435

    PubMed  CAS  Google Scholar 

  • Brinkmann OA, Müller KM (1989) What’s new in intraperitoneal test on Kevlar (asbestos substitute)? Pathol Res Pract 185:412–417

    PubMed  CAS  Google Scholar 

  • Brown JW, Kristensen KAB, Monroe LS (1968) Peritoneal mesothelioma following pneumoperitoneum maintained for twelve years: report of a case. Am J Dig Dis 13:830–835

    PubMed  CAS  Google Scholar 

  • Bültzingslöwen F von, Siernon G (1999) Die Therapic des malignen Pleuramesothelioms-ein fortdauerndes Dilemma. Pneumologie 53:266–275

    Google Scholar 

  • Caminschi I, Venetsanakos E, Leong CC, Garlepp MJ, Robinson BW, Scott B (1999) Cytokine gene therapy of mesothelioma. Immune and antitumor effects of transfected interleukin-12. Am J Respir Cell Mol Biol 21:347–356

    PubMed  CAS  Google Scholar 

  • Carbone M, Pass HI, Rizzo P et al. (1994) Simian virus 40-like DNA sequences in human pleural mesothelioma. Oncogene 9: 1781–1790

    PubMed  CAS  Google Scholar 

  • Carbone M, Rizzo P, Grimley PM et al. (1997a) Simian virus-40 large-T antigen binds p53 in human mesotheliomas. Nat Med 3:908–912

    PubMed  CAS  Google Scholar 

  • Carbone M, Rizzo P, Pass HI (1997b) Simian virus 40, poliovaccines and human tumors: a review of recent developments. Oncogene 15:1877–1888

    PubMed  CAS  Google Scholar 

  • Center R, Lukeis R, Dietzsch E, Gillespie M, Garson OM (1993) Molecular deletion of 9p sequences in non-small cell lung cancer and malignant mesothelioma. Genes Chromosomes Cancer 7:47–53

    PubMed  CAS  Google Scholar 

  • Cheng JQ, Jhanwar SC, Lu YY, Testa JR (1993) Homozygous deletions within 9p21-p22 identify a small critical region of chromosomal loss in human malignant mesotheliomas. Cancer Res 53:4761–4763

    PubMed  CAS  Google Scholar 

  • Cheng JQ, Jhanwar SC, Klein WM et al. (1994) p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res 54:5547–5551

    PubMed  CAS  Google Scholar 

  • Cicala C, Pompetti F, Nguyen P, Dixon K, Levine AS, Carbone M (1992) SV40 small t deletion mutants preferentially transform mononueIear phagocytes and B lymphocytes in vivo. Virology 190:475–479

    PubMed  CAS  Google Scholar 

  • Cicala C, Pompetti F, Carbone M (1993) SV40 induces mesotheliomas in hamsters. Am J Pathol 142:1524–1533

    PubMed Central  PubMed  CAS  Google Scholar 

  • Cristaudo A, Vivaldi A, Sensales G et al. (1995) Molecular biology studies on mesothelioma tumor samples: preliminary data on H-ras, p21, and SV40. J Environ Pathol Toxicol Oncol 14:29–34

    PubMed  CAS  Google Scholar 

  • Dawson A, Gibbs A, Browne K, Pooley F, Griffiths M (1992) Familial mesothelioma. Details of 17 cases with histopathologic findings and mineral analysis. Cancer 70: 1183–1187

    PubMed  CAS  Google Scholar 

  • De Luca A, Baldi A, Esposito V et al. (1997) The retinoblastoma gene family pRb/p105, p107, pRb2/p130 and simian virus-40 large T-antigen in human mesotheliomas. Nat Med 3:913–916

    PubMed  Google Scholar 

  • Donna A, Betta PG (1982) Mesodermomas: a new embryological approach to primary tumours of coelomic surfaces. Histopathology 5:31–44

    Google Scholar 

  • Donna A, Betta PG (1986) Differentiation towards cartilage and bone in a primary tumour of pleura. Further evidence in support of the concept of “mesodermoma”. Histopathology 10:101–108

    PubMed  CAS  Google Scholar 

  • Donna A, Betta PG, Bianchi V et al. (1991) A new insight into the histogenesis of “mesodermomas”-malignant mesotheliomas. Histopathology 19:239–244

    PubMed  CAS  Google Scholar 

  • Elmes PC, Simpson JC (1976) The clinical aspects of mesothelioma. QJM 45:427–429

    PubMed  CAS  Google Scholar 

  • Fitzpatrick DR, Bielefeldt-Ohmann H, Himheck RP, Jarnicki AG, Marzo AL, Robinson BW (1994) Transforming growth factor-beta: antisense RNA-mediated inhibition affects anchorage-independent growth, tumorigenicity and tumor-infiltrating T-cells in malignant mesothelioma. Growth Factors 11:29–44

    PubMed  CAS  Google Scholar 

  • Flejter WL, Li FP, Antman KH, Testa JR (1989) Recurring loss involving chromosomes 1, 3, and 22 in malignant mesothelioma: possible sites of tumor suppressor genes.Genes Chromosomes Cancer 1:148–154

    PubMed  CAS  Google Scholar 

  • Frizelle SP, Grim J, Zhou J et al. (1998) Re-expression of p16INK4a in mesothelioma cells results in cell cycle arrest, cell death, tumor suppression and tumor regression. Oncogene 16:3087–3095

    PubMed  CAS  Google Scholar 

  • Gilks B, Hegedus C, Freeman H, Fratkin L, Churg A (1988) Malignant peritoneal mesothelioma after remote abdominal radiation. Cancer 61:2019–2021

    PubMed  CAS  Google Scholar 

  • Gillissen A, Wiethege T (1996) Zelluläre Reaktionen der Lunge auf Mineralfasern. Pneumologie 50:5–17

    PubMed  CAS  Google Scholar 

  • Hagemeijer A, Versnel MA, Van Drunen E et al. (1990) Cytogenetic analysis of malignant mesothelioma. Cancer Genet Cytogenet 47:1–28

    PubMed  CAS  Google Scholar 

  • Hammar SP, Bolen JW (1988) Pleural neoplasms. In: Dail DH, Hammar SP (eds) Pulmonary pathology, 1st edn. Springer, Berlin Heidelberg New York, pp 973–1028

    Google Scholar 

  • Hammond EC, Selikoff IJ, Churg J (1965) Neoplasia among insulation workers in the United States with special reference to intra-abdominal neoplasia. Ann N Y Acad Sci 132:519–525

    PubMed  CAS  Google Scholar 

  • Hammond EC, Selikoff IJ Scidman H (1970) Asbestos exposure, cigarette smoking and death rates. Ann N Y Acad Sci 330:473–490

    Google Scholar 

  • Harington JS, McGlashan ND (1998) South African asbestos: production, exports, and destinations, 1959-1993. Am J Ind Med 33:321–326

    Google Scholar 

  • Harvey P, Warn A, Dobbin S et al. (1998) Expression of HGF/SF in mesothelioma cell lines and its effects on cell motility, proliferation and morphology. Br J Cancer 77:1052–1059

    PubMed Central  PubMed  CAS  Google Scholar 

  • Heineman EF, Bernstein L, Stark AD, Spirtas R (1996) Mesothelioma, asbestos, and reported his tory of cancer in first-degree relatives. Cancer 77:549–554

    PubMed  CAS  Google Scholar 

  • Hueper WC (1964) Cancer induction by polyurethan and polysilicone plastics. J Natl Cancer Inst 33:1005–1027

    PubMed  CAS  Google Scholar 

  • Huncharek M, Kelsey K, Muscat J, Christiani D (1996) Parental cancer and genetic predisposition in malignant pleural mesothelioma: a case-control study. Cancer Lett 102:205–208

    PubMed  CAS  Google Scholar 

  • Huzly A (1989) Parietale Pleurektomie bei der sekundären Pleurakarzinose. Z Herz Thorax Gefäßchir 3:80–83

    Google Scholar 

  • Jones JS (1993) The formation and function of the mesothelioma panel of the Commission of the European Communities. Commission of the European Communities. Office for Official Publications of the European Communities, Brussels

    Google Scholar 

  • Kallioniemi A, Kallioniemi OP, Sudar D et al. (1992) Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science 258:818–821

    PubMed  CAS  Google Scholar 

  • Karakoca Y, Emri S, Cangir AK, Baris YI (1997) Environmental pleural plaques due to asbestos and fibrous zeolite exposure in Turkey. Indoor Built Environ 6:100–105

    CAS  Google Scholar 

  • Katschinski HU, Müller KM (1994) Pleuramesotheliome im Raum Dresden 1964-1987. Arbeitsmed Sozialmed Umweltmed 7:284–288

    Google Scholar 

  • Ke Y, Reddel RR, Gerwin BI et al. (1989) Establishment of a human in vitro mesothelial cell model system for investigating mechanisms of asbestos-induced mesothelioma. Am J Pathol l34:979–991

    Google Scholar 

  • Kivipensas P, Bjorkqvist AM, Karhu R et al. (1996) Gains and losses of DNA sequences in malignant mesothelioma by comparative genomic hybridization. Cancer Genet Cytogenet 89:7–l3

    PubMed  CAS  Google Scholar 

  • Klemperer P, Rabin CB (1931) Primary neoplasms of the pleura: a report of five cases. Arch Pathol Lab Med 11:385–412

    Google Scholar 

  • Knuutila S, Armengol G, Bjorkqvist AM et al. (1998) Comparative genomic hybridization study on pooled DNAs from tumors of one clinical-pathological entity. Cancer Genet Cytogenet 100:25–30

    PubMed  CAS  Google Scholar 

  • König JE, Tolnay E, Wiethege T, Müller KM (2000) Co-Dexpression of vascular endothelial growth factor and its receptor flt-1 in malignant pleural mesothelioma. Respiration 67:36–40

    PubMed  Google Scholar 

  • Krismann M, Wiethege T, Müller K (1999) Calretinin and p53 as markers for differentiation between reactive and neoplastic pleuralIesions? Virchows Arch 435:287

    Google Scholar 

  • Krismann M, Müller KM, Jaworska M, Johnen G (2000) Severe chromosomal aberrations in pleural mesotheliomas with unusual mesodermal features-comparative genomic hybridization evidence for a mesothelioma subgroup. J Mol Diag 2:209–216

    CAS  Google Scholar 

  • Kucharczuk JC, Randazzo B, Chang MY et al. (1997) Use of a “replication-restricted” herpes virus to treat experimental human malignant mesothelioma. Cancer Res 57:466–471

    PubMed  CAS  Google Scholar 

  • Lanuti M, Gao GP, Force SD et al. (1999) Evaluation of an EIE4-deleted adenovirus expressing the herpes simplex thymidine kinase suicide gene in cancer gene therapy. Hum Gene Ther 10:463–475

    PubMed  CAS  Google Scholar 

  • Lee WC, Testa JR (1999) Somatic genetic alterations in human malignant mesothelioma. Int J Oncol 14:181–188

    PubMed  CAS  Google Scholar 

  • Lee WC, Balsara B, Liu Z, Jhanwar SC, Testa JR (1996) Loss of heterozygosity analysis defines a critical region in chromosome Ip22 commonly deleted in human malignant mesothelioma. Cancer Res 56:4297–4301

    PubMed  CAS  Google Scholar 

  • Leers MPG, Aarts MMJ, Theunissen PHMH (1998) E-cadherin and calretinin: a useful combination of immunochemical markers for differentiation between mesothelioma and metastatic adenocarcinoma. Histopathology 32:209–216

    PubMed  CAS  Google Scholar 

  • Libbus BL, Craighead JE (1988) Chromosomal translocations with specific breakpoints in asbestos-induced rat mesotheliomas. Cancer Res 48:6455–6461

    PubMed  CAS  Google Scholar 

  • Lu YY, Jhanwar SC, Cheng JQ, Testa JR (1994) Deletion mapping of the short arm of chromosome 3 in human malignant mesothelioma. Genes Chromosomes Cancer 9:76–80

    PubMed  CAS  Google Scholar 

  • Lukacs KV, Porter CD, Pardo OE et al. (1999) In vivo transfer of bacterial marker genes results in differing levels of gene expression and tumor progression in immunocompetent and immunodeficient mice. Rum Gene Ther 10:2373–2379

    CAS  Google Scholar 

  • Mark J (1978) Monosomy 14, monosomy 22 and 13q-three chromosomal abnormalities observed in cells of two malignant mesotheliomas studied by banding techniques. Acta Cytol 22:398–401

    PubMed  CAS  Google Scholar 

  • Martinis UJ, Radovic VR (1965) Pleural mesothelioma in a patient with pulmonary tuberculosis. Report of a case. Dis Chest 47:568–570

    PubMed  CAS  Google Scholar 

  • Marzo AL, Fitzpatrick DR, Robinson BW, Scott B (1997) Antisense oligonucleotides specific for transforming growth factor beta2 inhibit the growth of malignant mesothelioma both in vitro and in vivo. Cancer Res 57:3200–3207

    PubMed  CAS  Google Scholar 

  • Matker CM, Rizzo P, Pass HI et al. (1998) The biological activities of simian virus 40 large-T antigen and its possible oncogenic effects in humans. Monaldi Arch Chest Dis 53:193–197

    PubMed  CAS  Google Scholar 

  • Maurer R, Egloff B (1975) Malignant peritoneal mesothelioma after cholangiography with thorotrast. Cancer 36: 1381–1385

    PubMed  CAS  Google Scholar 

  • Maximow A (1927) über das Mesothel (Deckzellen der serösen Häute) und die Zellen der serösen Exsudate. Untersuchungen an entzündetem Gewebe und an Gewebskulturen. Arch Exp Zellforsch 4: 1–42

    Google Scholar 

  • McCaughey WT, McDonald AD (1977) Epidemiology of mesothelioma from estimated incidence. Prev Med 6:426–446

    Google Scholar 

  • McClure HM, Graham CE (1973) Malignant uterine mesotheliomas in squirrel monkeys following diethylstilbestrol administration. Lab Anim Sci 23:493–498

    PubMed  CAS  Google Scholar 

  • McDonald JC (1985) Health implications of environmental exposure to asbestos. Environ Health Perspect 62:319–328

    PubMed Central  PubMed  CAS  Google Scholar 

  • McDonald AD, McDonald JC (1973) Epidemiologie surveillance of mesothelioma in Canada. Can Med Assoc J 109:359–362

    PubMed Central  PubMed  CAS  Google Scholar 

  • McDonald AD, McDonald JC (1980) Malignant mesothelioma in North America. Cancer 46:1650–1656

    PubMed  CAS  Google Scholar 

  • Meloni AM, Stephenson CF, Li FP, Sandberg AA (1992) del(6q) as a possible primary change in malignant mesothelioma [published erratum appears in Cancer Genet Cytogenet 1992 61:110]. Cancer Genet Cytogenet 59:57-61

    Google Scholar 

  • Metcalf RA, Welsh JA, Bennett WP et al. (1992) p53 and Kirsten-ras mutations in human mesothelioma cell lines. Cancer Res 52:2610–2615

    PubMed  CAS  Google Scholar 

  • Mor O, Yaron P, Huszar M et al. (1997) Absence of p53 mutations in malignant mesotheliomas. Am J Respir Cell Mol Biol16:9–l3

    PubMed  CAS  Google Scholar 

  • Motherby H, Marcy T, Hecker M et al. (1998) Static DNA cytometry as a diagnostic aid in effusion cytology. 1. DNA aneuploidy for identification and differentiation of primary and secondary tumors of the serous membranes. Anal Quant Cytol Histol20:153–161

    PubMed  CAS  Google Scholar 

  • Müller KM (1997) Mesotheliome-Pathologie/Pathogenese/ Mesotheliomregister. Pneumologie 51:335–344

    PubMed  Google Scholar 

  • Mutti L, Carbone M, Giordano GG, Giordano A (1998) Simian virus 40 and human cancer. Monaldi Arch Chest Dis 53:198–201

    PubMed  CAS  Google Scholar 

  • National Institute for Occupational Safety and Health (1981) Ethylene oxide: evidence of carcinogenicity. 35. NIOSH Current Intelligence Bulletin. NIOSH, Cineinnati, OH

    Google Scholar 

  • Om S, Odden S, Osnes M (1991) [Familial clustering of asbestos-related diseases]. Tidsskr N or Laegeforen 111: 1099–1101

    Google Scholar 

  • Orosz Z, Nagy P, Szentirmay Z, Zalatnay A, Hauser P (1999) Epithelial mesothelioma with deciduoid features. Virchows Arch 434:263–266

    PubMed  CAS  Google Scholar 

  • Otte KE, Sigsgaard TI, Kjaerulff J (1990) [Massive exposure to asbestos and malignant mesothelioma, familial accumulation]. Ugeskr Laeger 152:3013–3014

    PubMed  CAS  Google Scholar 

  • Pass HI, Kennedy RC, Carbone M (1996) Evidence for and implications of SV 40-like sequences in human mesotheliomas. Important Adv Oncol 1996:89–108

    Google Scholar 

  • Pepper C, Jasani B, Navabi H, Wynford-Thomas D, Gibbs AR (1996) Simian virus 40 large T antigen (SV40LTAg) primer specific DNA amplification in human pleural mesothelioma tissue. Thorax 51: 1074–1076

    PubMed Central  PubMed  CAS  Google Scholar 

  • Peterson JT, Greenberg SD, Buffler PA (1984) Non-asbestosrelated malignant mesothelioma. A review. Cancer 54:951–960

    Google Scholar 

  • Pogrebniak HW, Lubensky IA, Pass BI (1993) Differential expression of platelet derived growth factor-beta in malignant mesothelioma: a clue to future Therapics? Surg Oncol 2:235–240

    PubMed  CAS  Google Scholar 

  • Popescu NC, Chahinian AP, DiPaolo JA (1988) Nonrandom chromosome alterations in human malignant mesothelioma. Cancer Res 48:142–147

    PubMed  CAS  Google Scholar 

  • Prins JB, Williamson KA, Kamp MM et al. (1998) The gene for the cyclin-dependent-kinase-4 inhibitor, CDKN2A, is preferentially deleted in malignant mesothelioma. Int J Cancer 75:649–653

    PubMed  CAS  Google Scholar 

  • Procopio A, Strizzi L, Giuffrida A et al. (1998) Human malignant mesothelioma of the pleura: new perspectives for diagnosis and therapy. Monaldi Arch Chest Dis 53:241–243

    PubMed  CAS  Google Scholar 

  • Ribotta M, Roseo F, Salvio M et al. (1998) Recurrent chromosome 6 abnormalities in malignant mesothelioma. Monaldi Arch Chest Dis 53:228–235

    PubMed  CAS  Google Scholar 

  • Riddell RH, Goodman MJ, Moossa AR (1981) Peritoneal malignant mesothelioma in a patient with recurrent peritonitis. Cancer 48:134–139

    PubMed  CAS  Google Scholar 

  • Risberg B, Nickels J, Wagermark J (1980) Familial clustering of malignant mesothelioma. Cancer 45:2422–2427

    PubMed  CAS  Google Scholar 

  • Rosenberg LE, Schechter A (2000) Gene therapist, heal thyself. Science 287:1757

    Google Scholar 

  • Sanders CL, Jackson TA (1972) Induction of mesotheliomas and sarcomas from “hot spots” of 239PuO2 activity. Health Phys 22:755–759

    PubMed  CAS  Google Scholar 

  • Schoental R, Gibbard S (1972) Nasal and other tumours in rats given 3,4,5-trimethoxyeinnamaldehyde, a derivate of sinapaldehyd and of other x,b-unsaturated aldehydic wood lignin constituents. Br J Cancer 26:504–505

    PubMed Central  PubMed  CAS  Google Scholar 

  • Schwarzenberger P, Harrison L, Weinacker A et al. (1998a) The treatment of malignant mesothelioma with a gene modified cancer cell line: a phase I study. Hum Gene Ther 9:2641–2649

    PubMed  CAS  Google Scholar 

  • Schwarzenberger P, Harrison L, Weinacker A et al. (1998b) Gene therapy for malignant mesothelioma: a novel approach for an incurable cancer with increased incidence in Louisiana. J La State Med Soc 150:168–174

    PubMed  CAS  Google Scholar 

  • Sekido Y, Pass HI, Bader S et al. (1995) Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. Cancer Res 55:1227–1231

    PubMed  CAS  Google Scholar 

  • Shivapurkar N, Wiethege T, Wistuba II et al. (1999) Presence of simian virus 40 sequences in malignant mesotheliomas and mesothelial cell proliferations. J Cell Biochem 76: 181–188

    PubMed  CAS  Google Scholar 

  • Smythe WR, Hwang HC, Amin KM et al. (1994) Use of recombinant adenovirus to transfer the herpes simplex virus thymidine kinase (HSVtk) gene to thoracic neoplasms: an effective in vitro drug sensitization system. Cancer Res 54:2055–2059

    PubMed  CAS  Google Scholar 

  • Smythe WR, Hwang HC, Elshami AA, Amin KM, Albelda SM, Kaiser LR (1995) Differential sensitivity of thoracic malignant tumors to adenovirus-mediated drug sensitization gene therapy. J Thorac Cardiovasc Surg 109:626–630

    PubMed  CAS  Google Scholar 

  • Solheim P, Saeter G, Finnanger AM et al. (1992) Highdose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study. Br J Cancer 65:956–960

    PubMed Central  PubMed  CAS  Google Scholar 

  • Stenton SC (1997) Asbestos, Simian virus 40 and malignant mesothelioma. Thorax [Suppl 3] 52:S52–S57

    PubMed Central  PubMed  Google Scholar 

  • Sterman DH, Kaiser LR, Albelda SM (1998a) Gene therapy for malignant pleural mesothelioma. Hematol Oncol Clin North Am 12:553–568

    PubMed  CAS  Google Scholar 

  • Sterman DH, Treat J, Litzky LA et al. (1998b) Adenovirusmediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. Hum Gene Ther 9:1083–1092

    PubMed  CAS  Google Scholar 

  • Stewart DJ, Gertler SZ, Tomiak A et al. (1994) High dose doxorubicin plus cisplatin in the treatment of unresectable mesotheliomas: report of four cases. Lung Cancer 11:251–258

    PubMed  CAS  Google Scholar 

  • Stock RJ, Fu YS, Carter JR (1979) Malignant peritoneal mesothelioma following radiotherapy for seminoma of the testis. Cancer 44:914–919

    PubMed  CAS  Google Scholar 

  • Tagnon I, Blot WJ, Stroube RB et al. (1980) Mesothelioma associated with the shipbuilding industry in coastal Virginia. Cancer Res 40:3875–3879

    PubMed  CAS  Google Scholar 

  • Taguchi T, Jhanwar SC, Siegfried JM, Keller SM, Testa JR (1993) Recurrent deletions of specific chromosomal sites in 1p, 3p, 6q, and 9p in human malignant mesothelioma [published erratum appears in Cancer Res 1993 53:5063]. Cancer Res 53:4349–4355

    PubMed  CAS  Google Scholar 

  • Talerman A, Montero JR, Chilcote RR (1985) Diffuse malignant peritoneal mesothelioma in a 13-year-old girl. Report of a case and review of the literature. Am J Surg Pathol 9:73–80

    PubMed  CAS  Google Scholar 

  • Terao K (1978) Mesotheliomas induced by sterigmatocystin in Wistar rats. Gann 69:237–247

    PubMed  CAS  Google Scholar 

  • Tiainen M, Tammilehto L, Mattson K, Knuutila S (1988) Nonrandom chromosomal abnormalities in malignant pleural mesothelioma. Cancer Genet Cytogenet 33:251–274

    PubMed  CAS  Google Scholar 

  • Tiainen M, Tammilehto L, Rautonen J, Tuomi T, Mattson K, Knuutila S (1989) Chromosomal abnormalities and their correlations with asbestos exposure and survival in patients with mesothelioma. Br J Cancer 60:618–626

    PubMed Central  PubMed  CAS  Google Scholar 

  • Travis WD, Colby TV, Corrin B, Shimosato Y, Brambilla E, in collaboration with LH Sobin and pathologists from 14 countries (1999) Histological classification of lung and pleural tumours, 3rd edn. Springer, Berlin Heidelberg New York

    Google Scholar 

  • Treat J, Kaiser LR, Sterman DH et al. (1996) Treatment of advanced mesothelioma with the recombinant adenovirus H5.010RSVTK: a phase 1 trial (BB-IND 6274). Hum Genet Ther 7:2047–2057

    CAS  Google Scholar 

  • Versnel MA, Claesson-Welsh L, Hammacher A et al. (1991) Human malignant mesothelioma cell lines express PDGF beta-receptors whereas cultured normal mesothelial cells express predominantly PDGF alpha-receptors. Oncogene 6:2005–2011

    PubMed  CAS  Google Scholar 

  • Wagner JC, Sleggs CA, Marchand P (1960) Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med 17:260–271

    PubMed Central  PubMed  CAS  Google Scholar 

  • Walker C, Rutten F, Yuan X, Pass H, Mew DM, Everitt J (1994) Wilms’ tumor suppressor gene expression in rat and human mesothelioma. Cancer Res 54:3101–3106

    PubMed  CAS  Google Scholar 

  • Wiethege T, Philips S, Müller KM (1997) Calretinin als Marker zur Differentialdiagnose von Mesotheliomen und Adenokarzinomen. Verh Dtsch Ges Pathol 81:417

    Google Scholar 

  • Woitowitz HJ (1987) Epidemiologie und Prävention des malignen Pleuramesothelioms. Med Klin 82:578–581

    CAS  Google Scholar 

Download references

Authors
  1. Klaus-Michael Müller
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thorsten Wiethege
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michael Krismann
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Klaus Junker
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Georg Johnen
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Max-Delbrück-Centrum für Molekulare Medizin (MDC), Robert-Rössle-Str.10, 13122, Berlin-Buch, Germany

    Detlev Ganten  & Klaus Ruckpaul  & 

  2. Medizinische Universitätsklinik Knappschaftskrankenhaus, In der Schornau 23-25, 44892, Bochum-Langendreer, Germany

    Stephan A. Hahn  & Wolff Schmiegel  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Müller, KM., Wiethege, T., Krismann, M., Junker, K., Johnen, G. (2002). Molekulare Pathologie bösartiger pulmonaler und pleuraler Tumoren. In: Ganten, D., Ruckpaul, K., Hahn, S.A., Schmiegel, W. (eds) Molekularmedizinische Grundlagen von nicht-hereditären Tumorerkrankungen. Molekulare Medizin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-56297-6_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-56297-6_2

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-62572-5

  • Online ISBN: 978-3-642-56297-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation